Thunder Biotech reported raising $9.98 Million in an initial SEC Form D filing, from an offering of $10 Million
PRIVATEAug 22, 2022Late filing, first sale Sep 30, 2019$10M of $10M raised
Amount Raised
$9.98 Million
$9.98 Million sold, per SEC Form D (first sale Sep 30, 2019)
Round Type
Venture
ProvoBiotechnologyBiotechnology Research
Quick answer
Thunder Biotech raised $9.98 Million in a funding round, dated September 30, 2019. Thunder Biotech is based in Provo, Utah, United States.
How much did Thunder Biotech raise?
Thunder Biotech raised $9.98 Million in a funding round on September 30, 2019.
What does Thunder Biotech do?
Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors.
Where is Thunder Biotech based and how big is it?
Thunder Biotech is based in Provo, Utah, United States.
Who are the decision-makers at Thunder Biotech?
Fundz holds 1 contact at Thunder Biotech, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Thunder Biotech, and when
A new round usually means Thunder Biotech is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Thunder Biotech raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Thunder Biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Thunder Biotech. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Thunder Biotech
Location
180 North University Avenue
Provo, Utah, United States
About
Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors.
Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy.
Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Thunder Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.